Edition:
United States

Bioporto A/S (BIOPOR.CO)

BIOPOR.CO on Copenhagen Stock Exchange

1.71DKK
10:52am EST
Change (% chg)

kr.0.06 (+3.64%)
Prev Close
kr.1.65
Open
kr.1.67
Day's High
kr.1.71
Day's Low
kr.1.61
Volume
179,494
Avg. Vol
334,019
52-wk High
kr.5.40
52-wk Low
kr.1.40

BIOPOR.CO

Chart for BIOPOR.CO

About

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay... (more)
No analyst recommendations are available for BIOPOR.CO.

Overall

Beta: 0.08
Market Cap(Mil.): kr.235.12
Shares Outstanding(Mil.): 142.49
Dividend: --
Yield (%): --

Financials

  BIOPOR.CO Industry Sector
P/E (TTM): -- 29.74 30.35
EPS (TTM): -0.16 -- --
ROI: -56.18 15.90 15.27
ROE: -56.27 17.00 16.60

BRIEF-BioPorto private placement fully subscribed

* Board has decided to issue 12.9 million new shares against payment of 1.69 Danish crown per share

Nov 14 2016

BRIEF-BioPorto: Private placement of up to DKK 21.8 million

* Said on Friday had initiated cash issue, private placement, of up to 12.9 million new shares to selected shareholders, institutional and financial investors

Nov 14 2016

BRIEF-EPO approves BioPorto's NGAL cutoff patent for issue

* European Patent Office (EPO) announced, that BioPorto's NGAL Cutoff patent has been approved for issue

Nov 08 2016

BRIEF-BioPorto Q3 EBIT loss widens to DKK 7.1 million, outlook cut

* Q3 revenue 4.6 million Danish crowns ($687,480) versus 4.7 million crowns year ago

Nov 03 2016

BRIEF-BioPorto files pre-sub application for NGAL test to FDA

* Maintains expectation that approval can be obtained by mid-2018

Oct 10 2016

BRIEF-BioPorto Q2 EBIT loss increases to DKK 7.7 mln

* Q2 revenue 4.7 million Danish crowns ($703,382.22) versus 5.8 million crowns year ago

Aug 04 2016

BRIEF-BioPorto to reapply for FDA approval of NGAL Test

* Financial outlook for 2016 is maintained Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 04 2016

Earnings vs. Estimates

No consensus analysis data available.